

Figure 1

TOPICAL INDUCERS OF LANGERHANS CELL MIGRATION




Figure 2

DENDRITIC CELLS in LYMPH NODE after SKIN PAINTING






Figure 3

LYMPH NODE CELLULARITY after SKIN PAINTING



TUMOR GROWTH after SKIN PAINTING with PEPTIDE in Dilute DMSO

Figure 4



Intravaginal Application of Peptide and DBP Induces Protective Tumor Immunity

Figure 5






Figure 6


Tumor Specific Immunity Induced by Cutaneous Application of Tumor Peptide in concentrated DMSO followed by DBP



Lymph Node Dendritic Cells Induced by Topical Application of Dibutylphthalate Analogs




Quantitative Detection of Peptide:MHC Complexes on Langerhans Cells *in vitro*




A. Immunofluorescent Detection of SIINFEKL:K^b Complexes on Langerhans Cells *in vitro*

B. Half Life of SIINFEKL:K^b Complexes on Langerhans Cells *in vitro*

Antigen-bearing Dendritic Cells in Lymph Nodes after Ultrasound Application of Soluble Peptide followed by Migration Inducer



Antigen-bearing Dendritic Cells in Lymph Nodes after Injection of Soluble Protein or Peptide followed by Migration Inducer



Antigen-bearing Dendritic Cells in Lymph Nodes after Injection of Soluble Peptide with or without subsequent Migration Inducer




Fig. 12

Tumor-specific Immunity induced by a Single Injection of a Tumor Protein followed by a Topical Migration Inducer




Fig. 13





Fig. 14

Adjuvant Effects of Inducing Dendritic Cell Migration/Maturation



<u>Antigen⁺ Dendritic Cells</u>	<u>Antigen⁻ Dendritic Cells</u>
504 → 22,239	2,520 → 33,673
<u>Lymphocytes</u>	
6 x 10 ⁶ → 8.6 x 10 ⁶	